Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Net Income (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Net Income for 16 consecutive years, with $7.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 141.5% to $7.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.1 million, a 120.78% increase, with the full-year FY2024 number at $9.8 million, up 111.51% from a year prior.
  • Net Income was $7.6 million for Q3 2025 at Gyre Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $51.6 million in Q2 2022 to a low of -$81.7 million in Q4 2023.
  • A 5-year average of -$7.3 million and a median of -$1.8 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 453.2% in 2021, then skyrocketed 801.18% in 2024.
  • Gyre Therapeutics' Net Income stood at -$20.4 million in 2021, then crashed by 41.21% to -$28.8 million in 2022, then crashed by 183.77% to -$81.7 million in 2023, then skyrocketed by 99.34% to -$540000.0 in 2024, then skyrocketed by 1512.78% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Net Income are $7.6 million (Q3 2025), $2.2 million (Q2 2025), and $3.7 million (Q1 2025).